The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

The ambition to turn the Oxford–Cambridge corridor into “Europe’s Silicon Valley” is in danger of stalling unless the ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 — — Savolitinib has the potential to become the first selective ...

(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Composite endpoints are widely used in large randomised cardiovascular outcome trials. They are frequently referred to as ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

A recent decision clarifies that not every workplace complaint qualifies as protected activity, even when documented in ...

Nadia Sawalha shared her heartbreak following the death of her friend after fighting to reverse a block on a cancer drug that ...

While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.